以岭药业(002603) - 2024 Q4 - 年度业绩预告

Financial Performance - The company expects a net loss of between 60 million and 80 million yuan for the fiscal year 2024, a decline of 144.37% to 159.16% compared to the previous year's profit of 135.24 million yuan [3]. - The net profit after deducting non-recurring gains and losses is projected to be a loss of between 59.14 million and 79.14 million yuan, down 146.76% to 162.57% from last year's profit of 126.47 million yuan [3]. - Basic earnings per share are expected to be a loss of between 0.36 yuan and 0.48 yuan, compared to earnings of 0.81 yuan per share in the previous year [3]. Factors Affecting Performance - The significant decline in performance is attributed to the write-down of sales revenue for certain respiratory products nearing expiration, increased raw material costs, and high R&D expenditures [5]. Research and Development - The company maintains a strong commitment to R&D, with ongoing clinical trials for new products such as the pediatric Lianhua Qinggan Granules and the acceptance of the registration application for Chaihuang Lidan Capsules [7]. - In 2025, the company plans to enhance its core technological innovation capabilities and expand sales channels to increase market share and clinical value of its products [7].